As of early 2023, George Scangos held 6.98 million shares in Vir Biotechnology, which represents about 6.3% of the company. Over the years, his stock holdings have fluctuated significantly due to stock options and performance-based grants. In 2022, he had...

As of early 2023, George Scangos held 6.98 million shares in Vir Biotechnology, which represents about 6.3% of the company. Over the years, his stock holdings have fluctuated significantly due to stock options and performance-based grants. In 2022, he had most of his wealth tied to these holdings, seeing a peak compensation of nearly $20.7 million demonstrating a strong alignment between his performance and the company's financial success. His stock vested annually, including 111,000 restricted stock units in 2022, showcasing a commitment to long-term growth in the firm’s share value. This strategic ownership structure not only motivated him but also engendered confidence among investors, reflecting how executive ownership can directly correlate with company performance.